In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...
The battle over deregistration of the African Democratic Congress, ADC, and four other political parties took a dramatic ...
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results